Home Healthcare Pharmaceuticals Osteoporosis Drugs Market

Osteoporosis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, Others), By Route of Administration (Oral, Injectable) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Mitiksha Koul | Format: | Report Code: SR4443DR | Pages: 155
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Osteoporosis Drugs Market, By Drug Class 2022-2034 (USD MILLION/ Units)
    1. Bisphosphonates
    2. Selective Estrogen Inhibitors Modulator (SERM)
    3. Parathyroid Hormone Therapy
    4. Calcitonin
    5. Rank Ligand Inhibitors
    6. Others
  2. Osteoporosis Drugs Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Oral
    2. Injectable
  3. Regional Osteoporosis Drugs Market
    1. North America
      1. North America Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
      2. North America Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
      3. U.S. Osteoporosis Drugs Market
        1. U.S. Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. U.S. Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      4. Canada Osteoporosis Drugs Market
        1. Canada Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Canada Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
    2. Europe
      1. Europe Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
      2. Europe Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
      3. U.K. Osteoporosis Drugs Market
        1. U.K. Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. U.K. Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      4. Germany Osteoporosis Drugs Market
        1. Germany Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Germany Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      5. France Osteoporosis Drugs Market
        1. France Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. France Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      6. Spain Osteoporosis Drugs Market
        1. Spain Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Spain Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      7. Italy Osteoporosis Drugs Market
        1. Italy Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Italy Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      8. Russia Osteoporosis Drugs Market
        1. Russia Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Russia Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      9. Nordic Osteoporosis Drugs Market
        1. Nordic Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Nordic Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      10. Benelux Osteoporosis Drugs Market
        1. Benelux Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Benelux Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      11. Rest of Europe Osteoporosis Drugs Market
        1. Rest of Europe Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Rest of Europe Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
    3. APAC
      1. APAC Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
      2. APAC Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
      3. China Osteoporosis Drugs Market
        1. China Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. China Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      4. Korea Osteoporosis Drugs Market
        1. Korea Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Korea Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      5. Japan Osteoporosis Drugs Market
        1. Japan Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Japan Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      6. India Osteoporosis Drugs Market
        1. India Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. India Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      7. Australia Osteoporosis Drugs Market
        1. Australia Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Australia Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      8. Taiwan Osteoporosis Drugs Market
        1. Taiwan Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Taiwan Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      9. South East Asia Osteoporosis Drugs Market
        1. South East Asia Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. South East Asia Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      10. Rest of Asia-Pacific Osteoporosis Drugs Market
        1. Rest of Asia-Pacific Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Rest of Asia-Pacific Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
    4. Middle East and Africa
      1. Middle East and Africa Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
      2. Middle East and Africa Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
      3. UAE Osteoporosis Drugs Market
        1. UAE Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. UAE Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      4. Turkey Osteoporosis Drugs Market
        1. Turkey Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Turkey Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      5. Saudi Arabia Osteoporosis Drugs Market
        1. Saudi Arabia Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Saudi Arabia Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      6. South Africa Osteoporosis Drugs Market
        1. South Africa Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. South Africa Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      7. Egypt Osteoporosis Drugs Market
        1. Egypt Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Egypt Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      8. Nigeria Osteoporosis Drugs Market
        1. Nigeria Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Nigeria Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      9. Rest of MEA Osteoporosis Drugs Market
        1. Rest of MEA Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Rest of MEA Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
    5. LATAM
      1. LATAM Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
      2. LATAM Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
      3. Brazil Osteoporosis Drugs Market
        1. Brazil Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Brazil Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      4. Mexico Osteoporosis Drugs Market
        1. Mexico Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Mexico Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      5. Argentina Osteoporosis Drugs Market
        1. Argentina Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Argentina Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      6. Chile Osteoporosis Drugs Market
        1. Chile Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Chile Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      7. Colombia Osteoporosis Drugs Market
        1. Colombia Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Colombia Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
      8. Rest of LATAM Osteoporosis Drugs Market
        1. Rest of LATAM Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Bisphosphonates
          2. Selective Estrogen Inhibitors Modulator (SERM)
          3. Parathyroid Hormone Therapy
          4. Calcitonin
          5. Rank Ligand Inhibitors
          6. Others
        2. Rest of LATAM Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Injectable
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.